(IN BRIEF) At ESCMID Global 2025 in Vienna, AstraZeneca will present a comprehensive data package from its Vaccines & Immune Therapies portfolio, featuring 13 abstracts across oral and poster presentations. The Company aims to demonstrate its progress in developing innovative … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged AstraZeneca, AZD6563, Benjamin Moutier, bronchiectasis, COVID-19, ESCMID Global 2025, Fluenz, FluMist, hMPV, immunizations, infectious diseases, Klebsiella pneumoniae, monoclonal antibodies, mRNA, MRSA, preclinical data, Pseudomonas aeruginosa, Real-World Data, respiratory viral infections, RSV, serious bacterial infections, Staphylococcus aureus, Vaccines & Immune Therapies, variant-agnostic threshold, Vienna
(IN BRIEF) AstraZeneca presented significant advancements in the prevention of infectious diseases at IDWeek 2024, showcasing its dedication to addressing respiratory infections caused by RSV, hMPV, and COVID-19. The company revealed promising data across its portfolio, including Beyfortus, an antibody … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Media, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged AstraZeneca, Beyfortus, COVID-19, FluMist, hMPV, IDWeek 2024, Iskra Reic, IVX-A12, Respiratory Disease Prevention, RSV, safety, Vaccine Innovation
(IN BRIEF) FluMist, a needle-free nasal spray influenza vaccine, has been approved by the FDA for self-administration in the US, making it the first flu vaccine of its kind to be used at home. Adults up to 49 years old … Read the full press release
(IN BRIEF) AstraZeneca is set to present new data at the 12th annual IDWeek conference, emphasizing the role of long-acting antibodies and vaccines in safeguarding at-risk individuals from common infectious respiratory diseases. The company will share 15 abstracts, including oral … Read the full press release
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?